| | 614-39-1 Basic information More.. |
| Product Name: | Procainamide hydrochloride | | Synonyms: | 4-AMINO-N-[2'-(DIETHYLAMINO)ETHYL]BENZAMIDE HCL;4-AMINO-N-(2-DIETHYLAMINOETHYL)BENZAMIDE HYDROCHLORIDE;4-AMINOBENZOIC ACID 2-DIETHYLAMINOETHYLAMIDE HYDROCHLORIDE;PROCAINE AMIDE HYDROCHLORIDE;PROCAINAMIDE HYDROCHLORIDE;N-(2-DIETHYLAMINOETHYL)-4-AMINOBENZAMIDE HYDROCHLORIDE;TIMTEC-BB SBB001067;4-amino-n-(2-(diethylamino)ethyl)benzamidemonohydrochloride | | CAS: | 614-39-1 | | MF: | C13H22ClN3O | | MW: | 271.79 | | EINECS: | 210-381-7 | | Mol File: | 614-39-1.mol |  |
Use
Procainamide hydrochloride is metabolized through theaction of N-acetyltransferase. The product of enzymaticmetabolism of procainamide hydrochloride is N-acetylprocainamide(NAPA), which possesses only 25% of the activityof the parent compound.26 A study of the disposition ofprocainamide hydrochloride showed that 50% of the drugwas excreted unchanged in the urine, with 7% to 24% recoveredas NAPA.28,29 Unlike quinidine, procainamide hydrochlorideis bound only minimally to plasma proteins.Between 75% and 95% of the drug is absorbed from the gastrointestinaltract. Plasma levels appear 20 to 30 minutesafter administration and peak in about 1 hour.30Procainamide hydrochloride appears to have all of theelectrophysiological effects of quinidine. It diminishesautomaticity, decreases conduction velocity, and increasesaction potential duration and, thereby, the refractory periodof myocardial tissue. Clinicians have favored the use of procainamidehydrochloride for ventricular tachycardias andquinidine for atrial arrhythmias, even though the two drugsare effective in either type of disorder.
|
|
614-39-1
Recommend Suppliers |
|